Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Revenue (2016 - 2025)

China Pharma Holdings' Revenue history spans 16 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Revenue rose 8.11% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $4.1 million, down 8.49%, while the annual FY2025 figure was $4.1 million, 8.49% down from the prior year.
  • Revenue reached $1.2 million in Q4 2025 per CPHI's latest filing, up from $756217.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $2.9 million in Q4 2022 to a low of $756217.0 in Q3 2025.
  • Average Revenue over 5 years is $1.7 million, with a median of $1.6 million recorded in 2022.
  • Peak YoY movement for Revenue: soared 33.7% in 2021, then crashed 47.25% in 2024.
  • A 5-year view of Revenue shows it stood at $2.9 million in 2021, then increased by 1.09% to $2.9 million in 2022, then decreased by 26.41% to $2.1 million in 2023, then tumbled by 47.25% to $1.1 million in 2024, then grew by 8.11% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Revenue are $1.2 million (Q4 2025), $756217.0 (Q3 2025), and $1.0 million (Q2 2025).